Ustekinumab is a human IgG1κ monoclonal antibody that was generated using human immunoglobulin (hu-Ig) transgenic mice. This monoclonal antibody specifically binds to the p40 subunit of IL-12 and IL-23, thus preventing their association with the IL-12Rβ1 receptor expressed on the NK cell and T cell surface and resulting in reduced IL-12 and IL-23 mediated signaling, activation, and cytokine production. Ustekinumab was developed by Centocor and received FDA approval in 2009 for use in the treatment of psoriasis. Recently, it has been approved for the treatment of Crohn’s disease and ulcerative colitis. Ustekinumab is marketed under the trade name STELARA®.
In PBS pH 7.5